Type 1 diabetes and glycaemic management
Research activity centres on type 1 diabetes, with interest in automated insulin delivery, continuous glucose monitoring, exercise-related glucose control, and strategies to reduce hypoglycaemia and glycaemic variability.
- Insulin therapy optimisation
- Exercise-induced hypoglycaemia
- Glucagon-based glucose support
- Postprandial glucose excursions
Interest also extends to type 1 diabetes with chronic complications and to personalised glucose-lowering approaches in inherited forms of diabetes.
Diabetic kidney disease and chronic kidney disease
The sponsor funds work focused on diabetic kidney disease, chronic kidney disease, and preservation of renal function, including studies of albuminuria, eGFR decline, and renal oxygenation.
- Albuminuria reduction
- eGFR slope
- Urinary proteomics
- Renoprotective treatment
Research includes biomarker-guided identification of patients at risk of kidney damage and treatment strategies relevant to type 1 diabetes and type 2 diabetes.
Cardiovascular disease and vascular complications
Clinical research includes atherosclerotic cardiovascular disease, coronary plaque progression, microvascular function, and cardiovascular risk reduction in people with diabetes and obesity.
- Coronary artery disease
- Platelet aggregation
- Cardiovascular autonomic neuropathy
- Heart failure risk
There is also interest in vascular injury linked to diabetic nephropathy and in treatment approaches aimed at limiting progression of cardiovascular complications.
Obesity, metabolic disease, and post-bariatric disorders
Studies cover overweight and obesity, stable coronary artery disease in people with excess weight, and metabolic complications after bariatric surgery, including post-bariatric hypoglycaemia.
- Weight-related metabolic dysfunction
- Postmenopausal obesity
- Coronary plaque composition
- Hypoglycaemia after gastric bypass
These activities connect metabolic treatment with cardiovascular and glucose-related outcomes in adult populations.
MODY and precision treatment in monogenic diabetes
The sponsor also works in maturity-onset diabetes of the young, particularly HNF1A-MODY and HNF4A-MODY, with attention to treatment selection and glucose-lowering response.
- Monogenic diabetes
- Sulfonylurea therapy
- Personalised glucose control
- Inherited diabetes subtypes
Research in this area includes individuals previously managed as having type 1 diabetes or type 2 diabetes, reflecting interest in diagnostic refinement and tailored metabolic care.
